Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 176

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Direct antiviral agents (DAAs) - A new age in the treatment of hepatitis C virus infection

Spengler, Ulrich · 2018 · Pharmacology & Therapeutics

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.pharmthera.2017.10.009

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 98

  1. Abergel, 2016, Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: An open-label, multicentre, single-arm, phase 2 study, The Lancet Infectious Diseases, 16, 459, 10.1016/S1473-3099(15)00529-0 · doi:10.1016/s1473-3099(15)00529-0
  2. Abergel, 2016, Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection, Hepatology, 64, 1049, 10.1002/hep.28706 · doi:10.1002/hep.28706
  3. Afdhal, 2014, Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection, The New England Journal of Medicine, 370, 1483, 10.1056/NEJMoa1316366 · DOI · Paper page
  4. Afdhal, 2014, Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection, The New England Journal of Medicine, 370, 1889, 10.1056/NEJMoa1402454 · DOI · Paper page
  5. 2016, Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts, Journal of Hepatology, 65, 734, 10.1016/j.jhep.2016.05.045 · DOI · Paper page
  6. Appel, 2008, Essential role of domain III of nonstructural protein 5A for hepatitis C virus infectious particle assembly, PLoS Pathogens, 4, 10.1371/journal.ppat.1000035 · DOI · Paper page
  7. Bartenschlager, 2010, Hepatitis C virus replication cycle, Journal of Hepatology, 53, 583, 10.1016/j.jhep.2010.04.015 · DOI
  8. Bartenschlager, 2013, The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection, Nature Reviews. Microbiology, 11, 482, 10.1038/nrmicro3046 · DOI · Paper page
  9. Belli, 2016, Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study, Journal of Hepatology, 65, 524, 10.1016/j.jhep.2016.05.010 · DOI · Paper page
  10. Belli LS, Duvoux C (Coordinators) and panel of experts. (2017) ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients. Journal of Hepatology (Epub ahead of print). · DOI
  11. Bourlière, 2017, Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection, The New England Journal of Medicine, 376, 2134, 10.1056/NEJMoa1613512 · DOI · Paper page
  12. Buti, 2016, Simeprevir plus sofosbuvir for hepatitis C virus genotype 4 infection: A phase 3, open-label study, Journal of Hepatology, 64, S220, 10.1016/S0168-8278(16)00193-8 · doi:10.1016/s0168-8278(16)00193-8
  13. Calleja, 2017, Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort, Journal of Hepatology, 66, 1138, 10.1016/j.jhep.2017.01.028 · DOI · Paper page
  14. Charlton, 2015, Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease, Gastroenterology, 149, 649, 10.1053/j.gastro.2015.05.010 · DOI · Paper page
  15. Conti, 2016, Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals, Journal of Hepatology, 65, 727, 10.1016/j.jhep.2016.06.015 · DOI · Paper page
  16. Crespo, 2017, Real-world effectiveness and safety of oral combination antiviral therapy for hepatitis C virus genotype 4 infection, Clinical Gastroenterology and Hepatology, 15, 945, 10.1016/j.cgh.2017.02.020 · doi:10.1016/j.cgh.2017.02.020
  17. Curry, 2015, Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: An open label study, Gastroenterology, 148, 100, 10.1053/j.gastro.2014.09.023 · DOI · Paper page
  18. Curry, 2015, Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis, The New England Journal of Medicine, 373, 2618, 10.1056/NEJMoa1512614 · DOI · Paper page
  19. Deterding, 2017, Six weeks of ledipasvir/sofosbuvir treatment of acute hepatitis C virus genotype 1 monoinfection: The HepNet Acute HCV IV Study, The Lancet Infectious Diseases, 17, 215, 10.1016/S1473-3099(16)30408-X · DOI
  20. Dubuisson, 2014, Virology and cell biology of the hepatitis C virus life cycle – An updated, Journal of Hepatology, 61, S3, 10.1016/j.jhep.2014.06.031 · DOI · Paper page
  21. European Association for the Study of the Liver, 2017, EASL recommendations on treatment of hepatitis C 2016, Journal of Hepatology, 66, 153, 10.1016/j.jhep.2016.09.001 · DOI · Paper page
  22. Fattovich, 2004, Hepatocellular carcinoma in cirrhosis: Incidence and risk factors, Gastroenterology, 127, 35, 10.1053/j.gastro.2004.09.014 · DOI · Paper page
  23. Feld, 2015, Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection, The New England Journal of Medicine, 373, 2599, 10.1056/NEJMoa1512610 · DOI · Paper page
  24. Feld, 2016, Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks, Journal of Hepatology, 64, 301, 10.1016/j.jhep.2015.10.005 · DOI · Paper page
  25. Ferenci, 2014, ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV, The New England Journal of Medicine, 370, 1983, 10.1056/NEJMoa1402338 · DOI · Paper page
  26. Fontaine, 2015, Bradyarrhythmias associated with sofosbuvir treatment, The New England Journal of Medicine, 373, 1886, 10.1056/NEJMc1505967 · doi:10.1056/nejmc1505967
  27. Foster, 2015, Sofosbuvir and Velpatasvir for HCV genotype 2 and 3 infection, The New England Journal of Medicine, 373, 2608, 10.1056/NEJMoa1512612 · DOI · Paper page
  28. Fox, 2017, Comparative treatment effectiveness of direct acting antiviral regimens for hepatitis C: Data from the veterans administration, Journal of Gastroenterology and Hepatology, 32, 1136, 10.1111/jgh.13652 · DOI
  29. Gane, 2015, Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12weeks in patients with HCV genotype 3 or 6 infection, Gastroenterology, 149, 1454, 10.1053/j.gastro.2015.07.063 · doi:10.1053/j.gastro.2015.07.063
  30. Gane, 2016, High efficacy of ABT-493 and ABT-530 treatment in patients with HCV genotype 1 or 3 infection and compensated cirrhosis, Gastroenterology, 151, 651, 10.1053/j.gastro.2016.07.020 · DOI
  31. Gane, 2016, Sofosbuvir/velpatasvir in combination with ribavirin for 24weeks is effective retreatment for patients who failed prior NS5A-containing DAA regimens: Results of the retreatment study, Journal of Hepatology, 64, S147, 10.1016/S0168-8278(16)00037-4 · doi:10.1016/s0168-8278(16)00037-4
  32. Grebely, 2012, Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: Towards a vaccine, The Lancet Infectious Diseases, 12, 408, 10.1016/S1473-3099(12)70010-5 · DOI · Paper page
  33. Hedskog, 2015, Characterization of hepatitis C virus inter-geno-typic recombinant strains and associated virological response to sofosbuvir/ribavirin, Hepatology, 61, 471, 10.1002/hep.27361 · DOI
  34. Hernandez, 2013, Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors, Journal of Clinical Virology, 57, 13, 10.1016/j.jcv.2012.12.020 · doi:10.1016/j.jcv.2012.12.020
  35. Hézode, 2016, Sustained virologic response to daclatasvir and sofosbuvir, with or without ribavirin, among patients in the French daclatasvir ATU programme infected with HCV genotypes 4, 5 and 6, Journal of Hepatology, 64, S755, 10.1016/S0168-8278(16)01471-9 · doi:10.1016/s0168-8278(16)01471-9
  36. Hézode, 2015, Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): A randomised, open-label trial, Lancet, 385, 2502, 10.1016/S0140-6736(15)60159-3 · DOI · Paper page
  37. Hézode, 2016, Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed a daclatasvir-containing regimen, Hepatology, 63, 1809, 10.1002/hep.28491 · doi:10.1002/hep.28491
  38. Hézode, 2017, Sofosbuvir-daclatasvir simeprevir plus ribavirin in direct-acting antiviral–experienced patients with hepatitis C, Clinical Infectious Diseases, 64, 1615, 10.1093/cid/cix214 · DOI
  39. Hlaing, 2017, Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotypes 1–4 and 6 in Myanmar: Real-world experience, Journal of Viral Hepatitis, 24, 927, 10.1111/jvh.12721 · DOI
  40. Horsley-Silva, 2017, New therapies for hepatitis C virus infection, Gastroenterology & Hepatology, 13, 22
  41. Ioannou, 2016, Effectiveness of sofosbuvir, ledipasvir/sofosbuvir, or paritaprevir/ritonavir/-ombitasvir and dasabuvir regimens for treatment of patients with hepatitis C in the veterans affairs National Health Care System, Gastroenterology, 151, 457, 10.1053/j.gastro.2016.05.049 · DOI · Paper page
  42. Ioannou, 2017, HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma, Journal of Hepatology
  43. Jacobson, 2017, Efficacy of 8weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials, Gastroenterology, 153, 113, 10.1053/j.gastro.2017.03.047 · DOI · Paper page
  44. Jacobson, 2017, Safety and efficacy of elbasvir/grazoprevir in patients with hepatitis C virus infection and compensated cirrhosis: An integrated analysis, Gastroenterology, 152, 1372, 10.1053/j.gastro.2017.01.050 · doi:10.1053/j.gastro.2017.01.050
  45. Jacobson, 2017, American Gastroenterological Association Institute clinical practice update—Expert review: Care of patients who have achieved a sustained virologic response after antiviral therapy for chronic hepatitis C infection, Gastroenterology, 152, 1578, 10.1053/j.gastro.2017.03.018 · DOI
  46. Kowdley, 2014, Ledipasvir and sofosbuvir for 8 or 12weeks for chronic HCV without cirrhosis, The New England Journal of Medicine, 370, 1879, 10.1056/NEJMoa1402355 · DOI · Paper page
  47. Kozbial, 2016, Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment, Journal of Hepatology, 65, 756, 10.1016/j.jhep.2016.06.009 · DOI · Paper page
  48. Krishnan, 2015, Analysis of HCV genotype 1b resistance variants in Japanese patients treated with paritaprevir/ritonavir and ombitasvir, Antimicrobial Agents and Chemotherapy, 60, 1106, 10.1128/AAC.02606-15 · doi:10.1128/aac.02606-15
  49. Krishnan, 2015, Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir, Antimicrobial Agents and Chemotherapy, 59, 5445, 10.1128/AAC.00998-15 · DOI
  50. Kwo, 2017, Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis, Journal of Hepatology, 67, 263, 10.1016/j.jhep.2017.03.039 · DOI · Paper page
  51. Lawitz, 2016, Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2), Hepatology, 64, 360, 10.1002/hep.28422 · DOI · Paper page
  52. Lawitz, 2017, Short-duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trial, Hepatology, 65, 439, 10.1002/hep.28877 · doi:10.1002/hep.28877
  53. Lawitz, 2017, Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virus, Hepatology, 65, 1803, 10.1002/hep.29130 · doi:10.1002/hep.29130
  54. Leroy, 2016, Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+), Hepatology, 63, 1430, 10.1002/hep.28473 · DOI
  55. Manns, 2016, Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: A multicentre, open-label, randomised, phase 2 trial, The Lancet Infectious Diseases, 15, 685, 10.1016/S1473-3099(16)00052-9 · DOI · Paper page
  56. Mariño, 2017, High efficacy of sofosbuvir plus simeprevir in a large cohort of Spanish cirrhotic patients infected with genotypes 1 and 4, Liver International, 2017
  57. Masaki, 2008, Interaction of hepatitis C virus nonstructural protein 5A with core protein is critical for the production of infectious virus particles, Journal of Virology, 82, 7964, 10.1128/JVI.00826-08 · DOI
  58. Messina, 2015, Global distribution and prevalence of hepatitis C virus genotypes, Hepatology, 61, 77, 10.1002/hep.27259 · DOI · Paper page
  59. Nahon, 2017, Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications, Gastroenterology, 152, 142, 10.1053/j.gastro.2016.09.009 · DOI · Paper page
  60. Nelson, 2015, All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study, Hepatology, 61, 1127, 10.1002/hep.27726 · DOI · Paper page
  61. Ng, 2017, In vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS5A inhibitor pibrentasvir, Antimicrobial Agents and Chemotherapy, 61, 10.1128/AAC.02558-16 · doi:10.1128/aac.02558-16
  62. Pearlman, 2015, The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis, Gastroenterology, 148, 762, 10.1053/j.gastro.2014.12.027 · doi:10.1053/j.gastro.2014.12.027
  63. Pockros, 2016, Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease, Gastroenterology, 150, 1590, 10.1053/j.gastro.2016.02.078 · DOI · Paper page
  64. Pol, 2017, Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients, Journal of Hepatology, 66, 39, 10.1016/j.jhep.2016.08.021 · doi:10.1016/j.jhep.2016.08.021
  65. Poordad, 2016, Ombitasvir/¬parita-previr/r, dasabuvir and sofosbuvir treatment of patients with genotype 1 infection who failed a prior course of DAA therapy: The QUARTZ-I study, Journal of Hepatology, 64, S767, 10.1016/S0168-8278(16)01496-3 · doi:10.1016/s0168-8278(16)01496-3
  66. Poordad, 2017, Glecaprevir and pibrentasvir for 12weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment, Hepatology, 66, 389, 10.1002/hep.29081 · DOI · Paper page
  67. Poordad, 2014, ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis, The New England Journal of Medicine, 370, 1973, 10.1056/NEJMoa1402869 · DOI · Paper page
  68. Poordad, 2016, Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post liver transplantation recurrence, Hepatology, 63, 1493, 10.1002/hep.28446 · DOI · Paper page
  69. Powdrill, 2010, Inhibitors of the hepatitis C virus RNA-dependent RNA polymerase NS5B, Virus, 2, 2169, 10.3390/v2102169 · DOI
  70. Powdrill, 2010, Mechanism of hepatitis C virus RNA polymerase inhibition with dihydroxypyrimidines, Antimicrobial Agents and Chemotherapy, 54, 977, 10.1128/AAC.01216-09 · DOI
  71. Ramos, 2017, Interferon-free treatments in patients with hepatitis C genotype 1-4 infections in a real-world setting, World Journal of Gastrointestinal Pharmacology and Therapeutics, 8, 137, 10.4292/wjgpt.v8.i2.137 · doi:10.4292/wjgpt.v8.i2.137
  72. Reddy, 2015, Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis, Hepatology, 62, 79, 10.1002/hep.27826 · DOI · Paper page
  73. Reig, 2016, Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy, Journal of Hepatology, 65, 719, 10.1016/j.jhep.2016.04.008 · DOI · Paper page
  74. Rockstroh, 2017, Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: An open-label, single-arm trial, Lancet Gastroenterology & Hepatology, 2, 347, 10.1016/S2468-1253(17)30003-1 · DOI
  75. Roth, 2015, Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): A combination phase 3 study, Lancet, 386, 1537, 10.1016/S0140-6736(15)00349-9 · DOI · Paper page
  76. Sarrazin, 2016, Prevalence of resistance-associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir, Gastroenterology, 151, 501, 10.1053/j.gastro.2016.06.002 · doi:10.1053/j.gastro.2016.06.002
  77. Sarrazin, 2017, Late relapse versus HCV reinfection in patients with sustained virologic response after sofosbuvir-based therapies, Clinical Infectious Diseases, 64, 44, 10.1093/cid/ciw676 · DOI
  78. Sarrazin, 2010, Resistance to direct antiviral agents in patients with hepatitis C virus infection, Gastroenterology, 138, 447, 10.1053/j.gastro.2009.11.055 · DOI · Paper page
  79. Simmons, 2016, Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: A systematic review and meta-analysis, Clinical Infectious Diseases, 62, 683, 10.1093/cid/civ948 · DOI · Paper page
  80. Smith, 2016, Proposed update to the taxonomy of the genera Hepacivirus and Pegivirus within the Flaviviridae family, The Journal of General Virology, 97, 2894, 10.1099/jgv.0.000612 · DOI · Paper page
  81. Sulkowski, 2014, Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection, The New England Journal of Medicine, 370, 211, 10.1056/NEJMoa1306218 · DOI · Paper page
  82. Susser, 2017, Origin, prevalence and response to therapy of hepatitis C virus genotype 2k/1b chimeras, Journal of Hepatology, 67, 680, 10.1016/j.jhep.2017.05.027 · DOI
  83. Tapper, 2016, Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study, Hepatology, 64, 1893, 10.1002/hep.28782 · DOI
  84. Tellinghuisen, 2008, Regulation of hepatitis C virion production via phosphorylation of the NS5A protein, PLoS Pathogens, 4, 10.1371/journal.ppat.1000032 · doi:10.1371/journal.ppat.1000032
  85. Tellinghuisen, 2008, Identification of residues required for RNA replication in domains II and III of the hepatitis C virus NS5A protein, Journal of Virology, 82, 1073, 10.1128/JVI.00328-07 · doi:10.1128/jvi.00328-07
  86. Tong, 2017, Discovery of Ruzasvir (MK-8408): A potent, pan-genotype HCV NS5A inhibitor with optimized activity against common resistance-associated polymorphisms, Journal of Medicinal Chemistry, 60, 290, 10.1021/acs.jmedchem.6b01310 · doi:10.1021/acs.jmedchem.6b01310
  87. Waziry, 2017, Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression, Journal of Hepatology, 10.1016/j.jhep.2017.07.025 · DOI · Paper page
  88. Webster, 2015, Hepatitis C, Lancet, 385, 1124, 10.1016/S0140-6736(14)62401-6 · DOI · Paper page
  89. Welzel, 2017, Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): A single-arm, open-label, phase 3b trial, Lancet Gastroenterology & Hepatology, 2, 494, 10.1016/S2468-1253(17)30071-7 · DOI
  90. Welzel, 2017, Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses, Journal of Hepatology, 67, 224, 10.1016/j.jhep.2017.03.014 · DOI
  91. Welzel, 2016, Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort, Gut, 65, 1861, 10.1136/gutjnl-2016-312444 · doi:10.1136/gutjnl-2016-312444
  92. Wolk, 2000, Subcellular localization, stability, and trans-cleavage competence of the hepatitis C virus NS3-NS4A complex expressed in tetracycline-regulated cell lines, Journal of Virology, 74, 2293, 10.1128/JVI.74.5.2293-2304.2000 · DOI · Paper page
  93. Yoshida, 2015, Concordance of sustained virological response 4, 12, and 24weeks post-treatment with sofosbuvir-containing regimens forhepatitis C virus, Hepatology, 61, 41, 10.1002/hep.27366 · doi:10.1002/hep.27366
  94. Zayas, 2016, Coordination of hepatitis C virus assembly by distinct regulatory regions in nonstructural protein 5A, PLoS Pathogens, 12, 10.1371/journal.ppat.1005376 · doi:10.1371/journal.ppat.1005376
  95. Zeng, 2017, Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: A real-life observational study, Journal of Hepatology, 66, 1123, 10.1016/j.jhep.2017.01.025 · DOI
  96. Zeuzem, 2014, Sofosbuvir and ribavirin in HCV genotypes 2 and 3, The New England Journal of Medicine, 370, 1993, 10.1056/NEJMoa1316145 · DOI · Paper page
  97. Zeuzem, 2015, Grazoprevir-Elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: A randomized trial, Annals of Internal Medicine, 163, 1, 10.7326/M15-0785 · DOI · Paper page
  98. Zeuzem, 2017, NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome, Journal of Hepatology, 66, 910, 10.1016/j.jhep.2017.01.007 · doi:10.1016/j.jhep.2017.01.007

Cited by

See all 176

Metadata

Authors
Spengler, U.
Venue
Pharmacology & Therapeutics
Publisher
Elsevier BV
Published
2018-03
Volume
183
Pages
118-126
ISSN
0163-7258 (ISSN-L)
OpenAlex
W2762048449
Cited by
176
References
2
FWCI
14.63
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Direct antiviral agents (DAAs) - A new age in the treatment of hepatitis C virus infection. https://app.cochat.ai/papers/10.1016/j.pharmthera.2017.10.009
The paper
Spengler, U. (2018). Direct antiviral agents (DAAs) - A new age in the treatment of hepatitis C virus infection. Pharmacology & Therapeutics. https://doi.org/10.1016/j.pharmthera.2017.10.009

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.